Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR4 Phase 1b in Type 2 Diabetes
NCT06553248Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GZR4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Mar 2023; status: completed.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06553248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553248.